TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00081159
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
Study: NCT01940341
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet administered orally once daily
Study: NCT01509196
Drug: HIP0901 / Lipidilsupra
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
Study: NCT02688023
Drug: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
Study: NCT02864368
Drug: Tetanus-Diphtheria booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
Study: NCT02864368
Drug: Tetanus Pre-Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
Study: NCT01217021
Drug: [18F] MNI-558
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
Study: NCT02030041
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin in a dose of 40 mg will be provided to the study participants
Study: NCT02030041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided to the study participants
Study: NCT00003105
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02947152
Drug: HKT288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadherin-6-targeting antibody-drug conjugate for intravenous administration
Study: NCT03402984
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
Study: NCT01182246
Drug: AXP107-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa.
Study: NCT04158076
Drug: Ezetimibe/Rosuvastatin
Normalized name: EZETIMIBE/ROSUVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT01353040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration
Study: NCT00616122
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03283826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to ATA188
Study: NCT02354560
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
Study: NCT00002831
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
Study: NCT00002831
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
Study: NCT02122198
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Climara transdermal patch 0.075mg/day applied weekly months 6-9
Study: NCT02122198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03295162
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
Study: NCT00147498
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at a dose of 5 mg BID for 6 weeks
Study: NCT00147498
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at a dose of 15 mg BID for 6 weeks
Study: NCT00147498
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg BID for 6 weeks
Study: NCT02447874
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours
Study: NCT02447874
Drug: Arginine (Loading)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Study: NCT02447874
Drug: Arginine (Continuous)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Study: NCT04542356
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
Study: NCT03331289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
Study: NCT01963728
Drug: Insulin, Isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dosing based on fasting morning glucose levels
Study: NCT00931697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-encapsulated placebo to maintain blinding
Study: NCT02004197
Drug: Quadruple Allopathic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004197
Drug: Pylorex plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03100344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)
Study: NCT04216459
Drug: intravenous vitamin C plus thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Study: NCT04480762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the SHR-1703
Study: NCT03202459
Drug: Group C - placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
Study: NCT00349843
Drug: Marketed soft lens multipurpose disinfection regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00804960
Drug: Std IVF Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
Study: NCT03797872
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate up to 25mg/week as tolerated po or sc
Study: NCT01411202
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
Study: NCT03139812
Drug: Daily irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
Study: NCT03889314
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Statin Therapy
Study: NCT01750385
Drug: no antibiotic prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
Study: NCT01750385
Drug: second-generation cephalosporin
Normalized name: Second-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
Study: NCT03670212
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
Study: NCT03670212
Drug: Lactose Monohydrate Powder
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
Study: NCT02081534
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1722, oral tablet
Study: NCT02081534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid, double dummy technique
Study: NCT00535561
Drug: Ferrous sulfate plus levothyroxine
Normalized name: Ferrous Sulfate
DrugBank: Ferrous succinate (DB14489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
Study: NCT03405454
Drug: standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy treatment will be administered as per local institutional guidelines
Study: NCT02881437
Drug: IgHy10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub Cutaneous IgHy10 administration
Study: NCT00403234
Drug: Placebo BTDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
Study: NCT03303950
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00485394
Drug: vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT-551 0% ophthalmic solution, 2 drops 4 times daily
Study: NCT01888822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic placebo infusion before elective laparoscopic cholecystectomy
Study: NCT00854659
Drug: ABT-102
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID tablets, 7 days of treatment
Study: NCT00854659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID tablets, 7 days of treatment
Study: NCT01032304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule twice a day
Study: NCT00639483
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Study: NCT00639483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Study: NCT03577730
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
Study: NCT02289222
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
Study: NCT00834067
Drug: UNIRETIC® 15/25 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 15/25 mg
Study: NCT01725555
Drug: Fed treatment: AXL1717
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01135498
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT01279577
Drug: Medium dose TSO
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose TSO suspension
Study: NCT01279577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT01077843
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cox-2 inhibitor
Study: NCT01077843
Drug: Other Non-selective NSAIDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective NSAID
Study: NCT01251809
Drug: PEG-rASNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500, 1000 or 1500 U/m2 BSA single infusion
Study: NCT00844922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01081912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, no active substance, shells identical to active comparator capsules
Study: NCT02919436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-filled capsules identical to active drug
Study: NCT02950805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a placebo in either period 1 or period 2 by inhalation.
Study: NCT02950805
Drug: AZD5634
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
Study: NCT02459795
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00183274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: six month intervention with placebo drug
Study: NCT02062489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2#/day, PO, daily
Study: NCT02265770
Drug: VEC + HD-MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
Study: NCT02265770
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
Study: NCT01560767
Drug: peri-articular infiltration
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
Study: NCT01152710
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
Study: NCT03048903
Drug: Rheum Palmatum Root
Normalized name: RHEUM PALMATUM ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
Study: NCT01370317
Drug: MK-1029
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study: NCT01370317
Drug: Placebo for MK-1029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study: NCT02709564
Drug: placebo 400 sublingual
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
Study: NCT00543426
Drug: Fuzheng Huayu Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet,three times a day,four tablets one time
Study: NCT00543426
Drug: sham Fuzheng Huayu Tablets (placebo)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, three times a day, four tablets one time
Study: NCT00567320
Drug: Sugar pill or Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03610035
Drug: NPT189
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Study: NCT03610035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01181700
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 300 ug using inhaler A
Study: NCT01181700
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 300 ug using inhaler A
Study: NCT01181700
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 300 ug using inhaler B
Study: NCT01318551
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 20 mg
Study: NCT02716987
Drug: [18F]PGM299
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PGM299 injection
Study: NCT01318551
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 40 mg (optional)
Study: NCT01318551
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 80 mg (optional)
Study: NCT01394627
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg x 2
Study: NCT01394627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04744207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, once daily for 4 weeks
Study: NCT03875235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Study: NCT03965091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
Study: NCT03559491
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term release steroid injection
Study: NCT00117598
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day